Because retatrutide is still in clinical trials, candidate criteria are based on standard research parameters for metabolic and anti-obesity medications
For most patients, this feeling of sickness or mild nausea is temporary
Strategies for managing this period include maintaining close communication with your healthcare provider about side effects, using all available anti-nausea strategies proactively rather than reactively, accepting that some temporary discomfort accompanies effective treatment, focusing on the progress already made rather than the challenges remaining, and remembering that 85% of patients report minimal side effects by month four
Mistake 4: not accounting for dead space Every syringe has a small amount of dead space in the hub where the needle attaches
Abdominal cramping, bloating, and sometimes vomiting
Eli Lillys tirzepatide, marketed as Zepbound for people with obesity and Mounjaro for those with Type 2 diabetes, is another story